1 not yet recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Blastic Transformation of Chronic Myeloid Leukemia: new trials by email Literature Review of Blastic Transformation of Chronic Myeloid Leukemia trials Research Report on Blastic Transformation of Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML Asciminib add-on, Imatinib, Dasatinib - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia | Phase 2 | Not yet recruiting | The University of Hong Kong | 45 | 2026-03-30 | 2026-03-25 |
| Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate - B-Cell Lymphoma, Myelodysplastic Syndromes (MDS) | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 80 | 2022-11-01 | 2026-08-07 |
Hodgkin Disease (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Plasma Cell (1) · Lymphoma, B-Cell (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasms, Germ Cell and Embryonal (1)
Blood Protein Disorders (1) · Bone Marrow Diseases (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Myeloid (1) · Lymphatic Diseases (1) · Lymphoma (1)
Cyclophosphamide (1) · Dasatinib (1) · Imatinib Mesylate (1) · fludarabine (1) · fludarabine phosphate (1) · nilotinib (1)
M.D. Anderson Cancer Center (1) · The University of Hong Kong (1)
Hong Kong (1) · United States (1)
David Marin, MD (1)